

**ASX RELEASE**

**5 October 2022**

**ASX: NVU**

## **Placement and Repayment of Equity Facility**

### **Placement:**

Nanoveu Limited (**Nanoveu** or the **Company**) is pleased to announce the Company has received firm commitments from sophisticated and professional investors to raise \$1,000,000 (before costs) through the issue of 100,000,000 fully paid ordinary shares (**Shares**) in the Company (**Placement**) at an issue price of \$0.01 per Share (**Placement Shares**), together with 1 free attaching option exercisable at \$0.02 on or before the third anniversary of the issue of the Placement Shares for every 2 Shares issued, subject to shareholder approval which the Company aims to seek in November 2022 (**Placement Options**).

24,172,972 Shares will be issued under the Company's placement capacity under Listing Rule 7.1, 23,327,028 Shares will be issued using the Company's placement capacity under Listing Rule 7.1A and 52,500,000 shares will be subject to shareholder approval. The issue price meets the requirements of Listing Rule 7.1A.3, being more than 75% of the 15-day volume weighted average price of Nanoveu shares traded on ASX.

The timetable for the placement is as follows:

<b>Placement funds due for Tranche 1</b>	11 October 2022
<b>Issue of Tranche 1 Placement Shares</b>	12 October 2022
<b>Expected trading of Tranche 1 Placement Shares of 47,500,000 shares</b>	13 October 2022
<b>General meeting for approval of Placement Options and Tranche 2 Placement Shares</b>	November 2022
<b>Placement funds due for Tranche 2</b>	November 2022 – immediately after approval at the shareholder meeting
<b>Issue of 50,000,000 Placement Options and 52,500,000 Tranche 2 Placement Shares</b>	November 2022

62 Capital Pty Ltd acted as Lead Manager to the Placement and will be paid a capital raising fee of 6% of the gross proceeds raised under the Placement. 62 Capital may elect to be paid in Shares.

Placement funds raised will be used as follows:

- |                                    |           |
|------------------------------------|-----------|
| - Sales and marketing              | \$200,000 |
| - Repayment of an equity facility  | \$626,000 |
| - General working capital purposes | \$174,000 |

**Repayment of equity facility:**

Part of the proceeds will be used to repay the amount outstanding to the investor under the funding agreement announced to the ASX on 14 August 2020, being \$626,000. \$326,000 of that amount will be repaid by the Company by 4 November 2022, followed by five monthly instalments of \$60,000 each.

Nanoveu will also issue 7,500,000 options with an exercise price of \$0.02 and a 3 year term to the investor in consideration of a variation of the agreement to permit an early repayment of the amount outstanding. These options will be issued from the Company's placement capacity under Listing Rule 7.1.

- Ends -

This announcement has been authorised for release by the Board of Nanoveu.

**For further information, please contact:**

**Alfred Chong**  
**Managing Director and CEO**

t: +65 6557 0155

e: [info@nanoveu.com](mailto:info@nanoveu.com)

**About Nanoveu Limited**

We are technology innovators who specialize in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. <https://www.nanoveu.com/>

**Nanoshield** - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to a number of surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial



properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.

**EyeFly3D** - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.

**Customskins** - are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.

**EyeFyx** - currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.